Boehringer enriches cancer immunology portfolio with AMAL Therapeutics acquisition
AMAL’s lead vaccine, ATP128, is currently developed for stage IV colorectal cancer and is slated to begin first-in-human trials later this month.
Read More
Tag: therapeutics
Biogen completes Nightstar acquisition
The companies announced the acquisition in March this year, with the value estimated at approximately $800 million.
Read More
Sanofi ends option phase of rare disease alliance with Alnylam
Through the agreement Alnylam will advance an additional investigational asset in an undisclosed rare genetic disease.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
